• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/5/21 10:12:31 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PPBT alert in real time by email
    SC 13G/A 1 ea134669-sc13ga1nuss_purple.htm AMENDMENT NO.1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 1)* 

     

    (Rule 13d-102)

     

    Under the Securities Exchange Act of 1934

     

    PURPLE BIOTECH LTD.

    (Name of Issuer)

     

    American Depositary Shares, each ADS
    represents one (1) Ordinary Share, no par value
    (Title of Class of Securities)

     

    49803V107**

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** 49803V107 is the CUSIP number for the American Depository Shares traded on the Nasdaq Stock Market. The ISIN number for the Ordinary Shares is IL0007650166.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 49803V107   13G Page 2 of 12 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Pontifax (Israel) II L.P.

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (a) ☐

    (b) ☐

     

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    80,7531 ADSs

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    80,7531 ADSs

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    80,7531 ADSs

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐ 

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    0.5%

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    PN

     

    1.Pontifax Management II L.P. ("Pontifax Management") is the general partner of the Pontifax (Israel) II - Individual Investors, L.P., Pontifax (Israel) II L.P., and Pontifax (Cayman) II L.P., and Pontifax Management 2 G.P. (2007) Ltd. ("Pontifax Management GP") is the general partner of Pontifax Management. Mr. Kariv and Ran Nussbaum are directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the ADSs held by these entities.

     

     

     

     

    CUSIP No. 49803V107   13G Page 3 of 12 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Pontifax (Cayman) II L.P.

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (a) ☐

    (b) ☐

     

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    107,2051 ADSs

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    107,2051 ADSs

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    107,2051 ADSs

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐ 

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    0.6%

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    PN

     

    1.Pontifax Management is the general partner of the Pontifax (Israel) II - Individual Investors, L.P., Pontifax (Israel) II L.P., and Pontifax (Cayman) II L.P., and Pontifax Management GP is the general partner of Pontifax Management. Mr. Kariv and Ran Nussbaum are directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the ADSs held by these entities.

     

     

     

     

    CUSIP No. 49803V107   13G Page 4 of 12 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Ran Nussbaum

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (c) ☐

    (d) ☐

     

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    219,306 ADSs1

    7.

    Sole Dispositive Power

     

    0 

    8.

    Shared Dispositive Power

     

    219,306 ADSs1

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    219,306 ADSs1

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐ 

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    1.3%

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    IN

     

    1.Consists of (a) 31,348 ADSs owned by Pontifax (Israel) II - Individual Investors, L.P.; (b) 80,753 ADSs owned by Pontifax (Israel) II L.P., and (c) 107,205 ADSs owned by Pontifax (Cayman) II L.P. Pontifax Management is the general partner of the Pontifax (Israel) II - Individual Investors, L.P., Pontifax (Israel) II L.P., and Pontifax (Cayman) II L.P., and Pontifax Management GP is the general partner of Pontifax Management. Mr. Kariv and Ran Nussbaum are directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the ADSs held by these entities.

     

     

     

     

    CUSIP No. 49803V107   13G Page 5 of 12 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Tomer Kariv

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (e) ☐

    (f) ☐

     

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    219,306 ADSs1

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    219,306 ADSs1

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    219,306 ADSs1

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐ 

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    1.3%

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    IN

     

    1.Consists of (a) 31,348 ADSs owned by Pontifax (Israel) II - Individual Investors, L.P.; (b) 80,753 ADSs owned by Pontifax (Israel) II L.P., and (c) 107,205 ADSs owned by Pontifax (Cayman) II L.P. Pontifax Management is the general partner of the Pontifax (Israel) II - Individual Investors, L.P., Pontifax (Israel) II L.P., and Pontifax (Cayman) II L.P., and Pontifax Management GP is the general partner of Pontifax Management. Mr. Kariv and Ran Nussbaum are directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the ADSs held by these entities.

     

     

     

     

    CUSIP No. 49803V107   13G Page 6 of 12 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Pontifax Management II L.P.

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (g) ☐

    (h) ☐

     

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    219,306 ADSs1

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    219,306 ADSs1

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    219,306 ADSs1

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐ 

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    1.3%

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    PN

     

    1.Consists of (a) 31,348 ADSs owned by Pontifax (Israel) II - Individual Investors, L.P.; (b) 80,753 ADSs owned by Pontifax (Israel) II L.P., and (c) 107,205 ADSs owned by Pontifax (Cayman) II L.P. Pontifax Management is the general partner of the Pontifax (Israel) II - Individual Investors, L.P., Pontifax (Israel) II L.P., and Pontifax (Cayman) II L.P., and Pontifax Management GP is the general partner of Pontifax Management. Mr. Kariv and Ran Nussbaum are directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the ADSs held by these entities.

     

     

     

     

    CUSIP No. 49803V107   13G Page 7 of 12 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Pontifax Management 2 G.P. (2007) Ltd.

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (i) ☐

    (j) ☐

     

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    219,306 ADSs1

    7. 

    Sole Dispositive Power

     

    0 

    8.

    Shared Dispositive Power

     

    219,306 ADSs1

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    219,306 ADSs1

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐ 

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    1.3%

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    CO

     

    1.Consists of (a) 31,348 ADSs owned by Pontifax (Israel) II - Individual Investors, L.P.; (b) 80,753 ADSs owned by Pontifax (Israel) II L.P., and (c) 107,205 ADSs owned by Pontifax (Cayman) II L.P. Pontifax Management is the general partner of the Pontifax (Israel) II - Individual Investors, L.P., Pontifax (Israel) II L.P., and Pontifax (Cayman) II L.P., and Pontifax Management GP is the general partner of Pontifax Management. Mr. Kariv and Ran Nussbaum are directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the ADSs held by these entities.

     

     

     

     

    CUSIP No. 49803V107   13G Page 8 of 12 Pages

     

    Introductory Note: This Schedule 13G is filed on behalf of Pontifax (Israel) II L.P., a limited partnership organized under the laws of the State of Israel and Pontifax (Cayman) II, L.P., a limited partnership organized under the laws of the Cayman Islands, Pontifax Management II L.P., a limited partnership organized under the laws of the State of Israel, Pontifax Management 2 G.P. (2007) Ltd., an Israeli company, Ran Nussbaum and Tomer Kariv, in respect of ADSs of Purple Biotech Ltd. (formerly known as Kitov Pharma Ltd.).

     

    Item 1(a).Name of Issuer:

     

    PURPLE BIOTECH LTD.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    One Azrieli Center, Round Tower, 132 Menachem Begin Road, Tel Aviv 6701101, Israel

     

    Item 2(a).Name of Person Filing:

     

    This Statement is filed on behalf of Pontifax (Israel) II L.P., Pontifax (Cayman) II L.P., Pontifax Management II L.P., Pontifax Management 2 G.P. (2007) Ltd., Ran Nussbaum and Tomer Kariv.

     

    Item 2(b).Address of Principal Offices or, if None, Residence:

     

    The addresses of the Reporting Persons are:

    Pontifax (Israel) II L.P. - 14 Shenkar St. Herzliya, 46140, Israel

    Pontifax (Cayman) II, L.P. - PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands

    Pontifax Management II L.P. - 14 Shenkar St. Herzliya, 46140, Israel

    Pontifax Management 2 G.P. (2007) Ltd. – 14 Shenkar St. Herzliya, 46140, Israel

    Ran Nussbaum - 14 Shenkar St. Herzliya, 46140, Israel

    Tomer Kariv - 14 Shenkar St. Herzliya, 46140, Israel

     

    Item 2(c).Citizenship:

     

    Pontifax (Israel) II L.P. is organized in the State of Israel, Pontifax (Cayman) II L.P. is organized in the Cayman Islands, Pontifax Management II L.P. is organized in the State of Israel, Pontifax Management 2 G.P. (2007) Ltd. is incorporated in the State of Israel, Ran Nussbaum is a citizen of the State of Israel, and Tomer Kariv is a citizen of the State of Israel.

     

    Item 2(d).Title of Class of Securities: ADSs

      

    Item 2(e).CUSIP Number: 49803V107

     

     

     

     

    CUSIP No. 49803V107   13G Page 9 of 12 Pages

     

     

    Item 3.If the Statement is being filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the filing person is a: Not applicable.

      

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                                                  

      

    Item 4.Ownership.

     

      (a) Amount beneficially owned:

     

    219,306 ADSs1

     

      (b) Percent of class:

     

    1.3%1

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote: 0

     

      (ii) Shared power to vote or direct the vote: 219,306 ADSs1

     

      (iii) Sole power to dispose or to direct the disposition of: 0

     

      (iv) Shared power to dispose or to direct the disposition of: 219,306 ADSs1

     

    1.Consists of (a) 31,348 ADSs owned by Pontifax (Israel) II - Individual Investors, L.P.; (b) 80,753 ADSs owned by Pontifax (Israel) II L.P., and (c) 107,205 ADSs owned by Pontifax (Cayman) II L.P. Pontifax Management is the general partner of the Pontifax (Israel) II - Individual Investors, L.P., Pontifax (Israel) II L.P., and Pontifax (Cayman) II L.P., and Pontifax Management GP is the general partner of Pontifax Management. Mr. Kariv and Ran Nussbaum are directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the ADSs held by these entities.

     

     

     

    CUSIP No. 49803V107   13G Page 10 of 12 Pages

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person had ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 49803V107   13G Page 11 of 12 Pages

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 2, 2021

     

    PONTIFAX (ISRAEL) II L.P.  
         
    By: /s/ Pontifax Management II L.P.  
    Name:  Pontifax Management II L.P.  
    Title: General Partner  
         
    By: /s/ Pontifax Management 2 G.P. (2007) LTD.  
    Name: Pontifax Management 2 G.P. (2007) LTD.  
    Title: General Partner  
         
    By: /s/ Ran Nussbaum  
    Name: Ran Nussbaum  
    Title: Director  

     

    PONTIFAX (CAYMAN) II L.P.  
       
    By: /s/ Pontifax Management II L.P.  
    Name:   Pontifax Management II L.P.  
    Title: General Partner  
         
    By: /s/ Pontifax Management 2 G.P. (2007) LTD.  
    Name: Pontifax Management 2 G.P. (2007) LTD.  
    Title: General Partner  
         
    By: /s/ Ran Nussbaum  
    Name: Ran Nussbaum  
    Title: Director  

     

    PONTIFAX MANAGEMENT II L.P.  
       
    By: /s/ Pontifax Management 2 G.P. (2007) LTD.  
    Name:  Pontifax Management 2 G.P. (2007) LTD.  
    Title: General Partner  
         
    By: /s/ Ran Nussbaum  
    Name: Ran Nussbaum  
    Title: Director  

     

    PONTIFAX MANAGEMENT 2 G.P. (2007) LTD.  
       
    By: /s/ Ran Nussbaum  
    Name:  Ran Nussbaum  
    Title: Director  

     

    /s/ Ran Nussbaum  
    RAN NUSSBAUM  
         
    /s/ Tomer Kariv  
    TOMER KARIV  

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

    CUSIP No. 49803V107   13G Page 12 of 12 Pages

     

    EXHIBIT INDEX

     

    A.Joint Filing Agreement, dated as of February 2, 2021, by and among Pontifax (Israel) II L.P., Pontifax (Cayman) II L.P., Pontifax Management II L.P., Pontifax Management 2 G.P. (2007) Ltd., Ran Nussbaum and Tomer Kariv. (Incorporated by reference from the Schedule 13G filed by the Reporting Persons with respect to the Issuer on February 13, 2020).

     

     

     

     

     

    Get the next $PPBT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PPBT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PPBT
    Financials

    Live finance-specific insights

    See more
    • Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

      Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the year and the three months ended December 31, 2022. "We are reporting our 2022 financial results which are in line with our plans," said Gil Efron, Chief Executive Officer of Purple Biotech. "Our end-of-y

      2/8/23 7:12:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PPBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Purple Biotech Ltd.

      SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

      11/14/24 5:21:29 PM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Purple Biotech Ltd.

      SC 13G - PURPLE BIOTECH LTD. (0001614744) (Subject)

      2/14/24 3:49:16 PM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Purple Biotech Ltd. (Amendment)

      SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

      4/9/21 4:34:41 PM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PPBT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups

      Statistically significant efficacy in biomarker subgroup analyses was observed: 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup 61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase (MPO) subgroup90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score (CPS) subgroup The biomarkers identified in the Phase 2 study are planned to be used for patient selection in the next Phase 2b study REHOVOT, Israel, April

      4/30/25 7:00:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

      Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatment of colorectal cancerNT219's mechanism of action informs how it can restore efficacy of immunotherapies and expand the patient population that can benefit from immunotherapies REHOVOT, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today that two posters reporting new NT219 data being presented at the American Association for Cancer Research (AACR

      4/28/25 8:28:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer

      Findings show combination therapy of NT219 and 5-flourouracil (5-FU) inhibits colorectal cancer brain metastasis through the IRS2 pathway IRS2, a novel target of NT219, is identified as a driver of brain metastasis in colorectal cancer, by comprehensive research conducted by Prof. Wolf and Dr. Rubinek team at Tel Aviv University and Sourasky Medical Center REHOVOT, Israel, April 16, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, announced today the publication of an independent study titled "IRS2 as a driver of brain

      4/16/25 7:00:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PPBT
    SEC Filings

    See more
    • SEC Form 6-K filed by Purple Biotech Ltd.

      6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

      5/6/25 4:00:47 PM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Purple Biotech Ltd.

      6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

      4/30/25 7:02:02 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Purple Biotech Ltd.

      6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

      4/28/25 9:26:34 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PPBT
    Leadership Updates

    Live Leadership Updates

    See more
    • Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

      Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c

      12/20/23 8:05:00 AM ET
      $GMDA
      $PNT
      $PPBT
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

      Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany's business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune evasion and drug resistance, today announced that the CEO, Gil Efron, has been hospitalized following an accident and will be on medical leave that is expected to last several months while he undergoes rehabilitation to recover from h

      3/24/23 7:00:00 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Appoints Lior Fhima as Chief Financial Officer

      Seasoned financial executive strengthens management team  REHOVOT, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Lior Fhima, CPA, MBA, as Chief Financial Officer of the Company.  Mr. Fhima brings deep expertise in financial management in the pharmaceutical industry and strong managerial capabilities. "We are honored to welcome Lior Fhima to the executive management team," said Gil Efron, Ch

      11/2/22 7:37:26 AM ET
      $PPBT
      Biotechnology: Pharmaceutical Preparations
      Health Care